Advances in management of sickle cell disease.
Sickle cell disease is numerically as common as thalassaemia. However, it affects relatively under privileged population i.e. tribal population belonging to economically poor class and having inadequate access to education and modern health facilities. A recent explosion acknowledged in understanding the pathogenesis of this disease has lead to newer dimensions in treatment. Some of these viz. prevention of overwhelming bacterial infection, present indications and controversies regarding blood transfusion, prevention of stroke, acute chest syndrome, hydroxyurea therapy--probably the best disease modifying agent at the moment, stem cell transplantation--a cure and certain promising experimental therapies including gene therapy have been discussed in this review.
D000208:Acute Disease; D000293:Adolescent; D000755:Anemia, Sickle Cell / Q000150:complications / Q000628:therapy*; D000986:Antisickling Agents / Q000627:therapeutic use; D001424:Bacterial Infections / Q000209:etiology / Q000517:prevention & control; D001803:Blood Transfusion / Q000592:standards; D002648:Child; D002675:Child, Preschool; D004921:Erythropoietin / Q000627:therapeutic use; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D007223:Infant; D007231:Infant, Newborn; D011994:Recombinant Proteins; D012140:Respiratory Tract Diseases / Q000209:etiology / Q000517:prevention & control; D033581:Stem Cell Transplantation / Q000379:methods; D020521:Stroke / Q000209:etiology / Q000517:prevention & control; D013577:Syndrome
D000986:Antisickling Agents; D011994:Recombinant Proteins; D004921:Erythropoietin; D006918:Hydroxyurea